ストックスクリーナーアプリを入手
1.57
1.29%
0.02
アフターアワーズ：
1.57
前日終値:
$1.55
開ける：
$1.55
24時間の取引高:
478.42K
Relative Volume:
0.87
時価総額：
$66.31M
収益：
$88.55M
当期純損益:
$-53.21M
株価収益率:
-1.2134
EPS:
-1.2939
ネットキャッシュフロー:
$-29.48M
1週間 パフォーマンス:
+17.16%
1か月 パフォーマンス:
+23.62%
6か月 パフォーマンス:
-3.68%
1年 パフォーマンス:
-49.52%
1日の値動き範囲:
$1.50
$1.575
1週間の範囲:
$1.3377
$1.629
52週間の値動き範囲:
$1.13
$3.88
Pulmonx Corp Stock (LUNG) Company Profile
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.57 | 65.47M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | 開始されました | D. Boral Capital | Buy |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-06-04 | 開始されました | Lake Street | Buy |
| 2024-02-23 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 開始されました | Craig Hallum | Buy |
| 2023-02-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2021-12-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 開始されました | Citigroup | Buy |
| 2021-03-25 | 開始されました | Piper Sandler | Neutral |
| 2021-03-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-26 | 開始されました | BofA Securities | Buy |
| 2020-10-26 | 開始されました | Canaccord Genuity | Buy |
| 2020-10-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 開始されました | Stifel | Buy |
| 2020-10-26 | 開始されました | Wells Fargo | Equal Weight |
すべてを表示
Pulmonx Corp (LUNG) 最新ニュース
Pulmonx Corp stock (US74586W1018): Q1 2026 results highlight growth path in minimally invasive lung - AD HOC NEWS
Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spo - AD HOC NEWS
LUNG Technical Analysis | Trend, Signals & Chart Patterns | PULMONX CORP (NASDAQ:LUNG) - ChartMill
TradingKey - TradingKey
Why Pulmonx Corporation (LUNG) valuation makes sense when you dig deeper (Marginal Loss) 2026-05-11Buffered ETF - Newser
Pulmonx Corporation (LUNG) beats Q1 estimates with EPS improvement despite revenue growth; shares decline as investors focus on losses.AI Trading Community - Newser
Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart
Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan
Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView
Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Pulmonx (LUNG) Q1 2026 Earnings Transcript - AOL.com
Pulmonx Corporation (NASDAQ:LUNG) Q1 2026 Earnings Call Transcript - Insider Monkey
LUNG Maintained by D. Boral Capital -- Price Target Stays at $14 - GuruFocus
Pulmonx Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Pulmonx's (LUNG) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
Is Pulmonx (LUNG) 85.3% Undervalued After Q1 2026 Beats? EPS -$0 - GuruFocus
Pulmonx (LUNG) Projects 2026 Revenue Between $90M and $92M - GuruFocus
Pulmonx Q1 Earnings Call Highlights - MarketBeat
Pulmonx (LUNG) Reports Strong Q1 Revenue Growth - GuruFocus
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Pulmonx Q1 2026 reveals mixed results, stock dips - Investing.com Canada
Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Pulmonx Corp (NASDAQ:LUNG) Q1 2026 Revenue Miss and Falling Sales Drag Down Sentiment - ChartMill
Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Pulmonx Reports First Quarter 2026 Financial Results - The Manila Times
Pulmonx (NASDAQ: LUNG) Q1 revenue falls 9% but 2026 outlook reaffirmed - Stock Titan
No China sales cut Pulmonx revenue 9%, but 2026 forecast holds - Stock Titan
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference - The Manila Times
Pulmonx webcast set for May 12 Bank of America health conference - Stock Titan
Pulmonx Corp expected to post a loss of 33 cents a shareEarnings Preview - TradingView
LUNG (Pulmonx Corporation) rises 5.63% on narrower Q4 2025 losses and steady 8% year over year revenue growth.Management Guidance - UBND thành phố Hải Phòng
[ARS] Pulmonx Corp SEC Filing - Stock Titan
Executive pay and board votes at Pulmonx (NASDAQ: LUNG) 2026 meeting - Stock Titan
Pulmonx (LUNG) Projected to Post Earnings on Wednesday - MarketBeat
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk - Yahoo Finance
Pulmonx Corporation (NASDAQ:LUNG) Short Interest Update - MarketBeat
Pulmonx sets April 29 earnings release, 4:30 p.m. ET webcast - Stock Titan
LUNG Stock Price, Quote & Chart | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp stock (US74586W1018): Is its airway treatment edge strong enough to unlock new upside? - AD HOC NEWS
Pulmonx (NASDAQ:LUNG) Stock Price Up 2.3%Still a Buy? - MarketBeat
Pulmonx Insiders Forfeit On 14% Gains After Selling Stock - Sahm
How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance - Yahoo Finance
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com
Rate Hike: Is Pulmonx Corporation stock trending bullishWeekly Profit Summary & Safe Capital Growth Plans - baoquankhu1.vn
Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG) - Stock Titan
If You Invested $1,000 in Pulmonx Corp (LUNG) - Stock Titan
How The Pulmonx (LUNG) Narrative Is Resetting Around Execution Risks And Fair Value Assumptions - Yahoo Finance
Pulmonx Corp (LUNG) 財務データ
収益
当期純利益
現金流量
EPS
Pulmonx Corp (LUNG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| French Glendon E. III | President and CEO |
Mar 02 '26 |
Sale |
1.43 |
67,813 |
96,973 |
1,409,511 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Mar 02 '26 |
Sale |
1.43 |
7,732 |
11,057 |
365,734 |
| Lehman David Aaron | GENERAL COUNSEL |
Mar 02 '26 |
Sale |
1.43 |
12,237 |
17,499 |
240,755 |
1.27%
2.05%
大文字化:
|
ボリューム (24 時間):